{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T04:07:12Z","timestamp":1775534832619,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This study assessed the pharmacokinetic interactions between dolutegravir (DTG)-based antiretroviral therapy (ART) and immunosuppressants in solid organ transplantation (SOT) recipients with HIV and ART safety.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A phase IV, single-center, open-label, single-arm clinical trial (DTG-SOT, NCT03360682) including adult SOT recipients with HIV conducted between 2017 and 2019. People with HIV with plasma viral load &amp;lt;50\u2005copies\/mL during \u226512 months and receiving stable raltegravir-based ART during \u22656 months were switched to tenofovir disoproxil fumarate\/emtricitabine or lamivudine\/abacavir + DTG and followed up for 48 weeks. Immunosuppressant pharmacokinetic parameters were compared before and 2 weeks after ART switch (primary outcome). Efficacy and safety were analyzed at 48 weeks by intention-to-treat analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Nineteen consecutive participants (median, 57 years; interquartile range, 51\u201360), mostly liver recipients (63.2%), received DTG\/lamivudine\/abacavir (63.2%) and DTG + emtricitabine\/tenofovir disoproxil fumarate (36.8%). Pharmacokinetic parameters changed, albeit not significantly, before and after ART, for mycophenolic acid (maximum [Cmax] +63%, trough [Cmin] +53%, area under the curve [AUC] +16%; n = 7) and cyclosporine A (Cmax \u221264%, Cmin +14%, AUC \u221247%; n = 2), with smaller changes for tacrolimus (Cmax +14%, Cmin \u221229%, AUC \u22129%; n = 7). No participants experienced acute rejection or virological failure and CD4+ cell counts and percentages remained unchanged during follow-up. Three (15.8%) discontinued treatment because of adverse events. Estimated glomerular filtration rate decreased (P = 0.0015) and creatinine increased (P\u2005=\u20050.0001) slightly.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>DTG-based ART lacked clinically significant drug\u2013drug interactions with tacrolimus and mycophenolic acid. Switching to DTG-based ART was effective in people with HIV SOT recipients. More studies are needed to evaluate DTG safety in this setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf119","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:02:09Z","timestamp":1741766529000},"source":"Crossref","is-referenced-by-count":3,"title":["Dolutegravir-based Antiretroviral Therapy in People With HIV With Solid Organ Transplantation: A Single-arm Pilot Clinical Trial (DTG-SOT)"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8057-7755","authenticated-orcid":false,"given":"Jose M","family":"Miro","sequence":"first","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]},{"name":"Reial Academia de Medicina de Catalunya (RAMC) , Barcelona ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Malano-Barletta","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leire","family":"Berrocal","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Manzardo","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Castelli","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merc\u00e8","family":"Brunet","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Pharmacology and Toxicology, Biochemistry and Molecular Genetics, Biomedical Diagnostic Center (CDB), Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Octavi","family":"Roman","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Ambrosioni","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Cof\u00e1n","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Department of Nephrology and Kidney Transplantation, Institut Cl\u00ednic de Nefrologia i Urologia (ICNU), Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-2167","authenticated-orcid":false,"given":"Angela","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Department of Nephrology and Kidney Transplantation, Institut Cl\u00ednic de Nefrologia i Urologia (ICNU), Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), , Madrid ,","place":["Spain"]},{"name":"Universitat de Barcelona Liver Transplant Unit, Liver Unit, ICMDM, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Crespo","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), , Madrid ,","place":["Spain"]},{"name":"Universitat de Barcelona Liver Transplant Unit, Liver Unit, ICMDM, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Forner","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), , Madrid ,","place":["Spain"]},{"name":"Universitat de Barcelona Liver Transplant Unit, Liver Unit, ICMDM, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"\u00c1ngeles Castel","sequence":"additional","affiliation":[{"name":"Unit for Heart Failure and Heart Transplantation, Institut Cl\u00ednic Cardiovascular (ICCV), Hospital Cl\u00ednic \u2013 IDIBAPS, Universitat de Barcelona , Barcelona ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red Enfermedades Cardiovasculares (CIBERCV), , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Laguno","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montse","family":"Tuset","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Department of Pharmacy, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"de Lazzari","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]},{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), , Madrid ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Rimola","sequence":"additional","affiliation":[{"name":"Instituto de Salud Carlos III Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), , Madrid ,","place":["Spain"]},{"name":"Universitat de Barcelona Liver Transplant Unit, Liver Unit, ICMDM, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asunci\u00f3n","family":"Moreno","sequence":"additional","affiliation":[{"name":"Universitat de Barcelona Infectious Diseases Department and HIV\/AIDS Unit, Hospital Cl\u00ednic \u2013 IDIBAPS, , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"SOT in HIV-infected patients Working Group Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J M","family":"Miro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Malano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Manzardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Castelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Roman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ambrosioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bodro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Linares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Laguno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Rimola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Forner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Crespo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Londo\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Forns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Garcia-Valdecasas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Cofan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Diekmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Oppenheimer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M A","family":"Castel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Perez-Villa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Farrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Pereda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Tuset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Paredes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Lligo\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"de Lazzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Cruceta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Bonfill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J A","family":"Arnaiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025052712074654400_ofaf119-B1","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0956462416632428","article-title":"Prevalence and distribution of non-AIDS causes of death among HIV-infected individuals receiving antiretroviral therapy: a systematic review and meta-analysis","volume":"28","author":"Farahani","year":"2017","journal-title":"Int J STD AIDS"},{"key":"2025052712074654400_ofaf119-B2","first-page":"1975","article-title":"Liver transplantation in people living with HIV: still an experimental procedure or standard of care?","volume":"13","author":"Lynch","year":"2023","journal-title":"Life (Basel)"},{"key":"2025052712074654400_ofaf119-B3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1056\/NEJMsb020632","article-title":"Solid-organ transplantation in HIV-infected patients","volume":"347","author":"Halpern","year":"2002","journal-title":"N Engl J Med"},{"key":"2025052712074654400_ofaf119-B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11904-019-00440-x","article-title":"Solid organ transplantation in HIV-infected recipients: history, progress, and frontiers","volume":"16","author":"Werbel","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025052712074654400_ofaf119-B5","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1157\/13076175","article-title":"[GESIDA\/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]","volume":"23","author":"Mir\u00f3","year":"2005","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2025052712074654400_ofaf119-B6","doi-asserted-by":"crossref","first-page":"e13499","DOI":"10.1111\/ctr.13499","article-title":"Solid organ transplantation in the HIV-infected patient: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Blumberg","year":"2019","journal-title":"Clin Transplant"},{"key":"2025052712074654400_ofaf119-B7","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00134-019-05524-1","article-title":"Challenges in solid organ transplantation in people living with HIV","volume":"45","author":"Miro","year":"2019","journal-title":"Intensive Care Med"},{"key":"2025052712074654400_ofaf119-B8","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1080\/14656566.2019.1612364","article-title":"Pharmacotherapeutic management of HIV in transplant patients","volume":"20","author":"Spagnuolo","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"2025052712074654400_ofaf119-B9","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1089\/apc.2012.0169","article-title":"Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review","volume":"26","author":"Van Maarseveen","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"2025052712074654400_ofaf119-B10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1177\/10815589241252595","article-title":"Systematic review of the impact of protease-inhibitor-based combination antiretroviral therapy on renal transplant outcomes in recipients living with HIV infection","volume":"72","author":"Milosh","year":"2024","journal-title":"J Investig Med"},{"key":"2025052712074654400_ofaf119-B11","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1111\/j.1600-6143.2009.02684.x","article-title":"Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs","volume":"9","author":"Tricot","year":"2009","journal-title":"Am J Transplant"},{"key":"2025052712074654400_ofaf119-B12","author":"EACS"},{"key":"2025052712074654400_ofaf119-B13","first-page":"1","article-title":"Documento de consenso sobre el manejo de la patolog\u00eda renal en pacientes con infecci\u00f3n por VIH. (Consensus document on the evaluation and management of renal disease in HIV-infected patients","volume":"34","author":"G\u00f3rriz","year":"2014","journal-title":"Nefrolog\u00eda (Madrid)"},{"key":"2025052712074654400_ofaf119-B14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0956462416651528","article-title":"Integrase strand transferase inhibitors: the preferred antiretroviral regimen in HIV-positive renal transplantation","volume":"28","author":"Azar","year":"2017","journal-title":"Int J STD AIDS"},{"key":"2025052712074654400_ofaf119-B15","author":"Tivicay | European Medicines Agency"},{"key":"2025052712074654400_ofaf119-B16"},{"key":"2025052712074654400_ofaf119-B17","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-020-00898-8","article-title":"Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review","volume":"59","author":"Podany","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2025052712074654400_ofaf119-B18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5582\/bst.2011.v5.5.189","article-title":"Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S\/GSK 1349572)","volume":"5","author":"Waki","year":"2011","journal-title":"Biosci Trends"},{"key":"2025052712074654400_ofaf119-B19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s40268-020-00300-9","article-title":"Dolutegravir-based antiretroviral regimens for HIV liver transplant patients in real-life settings","volume":"20","author":"Cattaneo","year":"2020","journal-title":"Drugs R D"},{"key":"2025052712074654400_ofaf119-B20","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1016\/j.transproceed.2020.05.005","article-title":"Simultaneous deceased donor liver and kidney transplantation in a human immunodeficiency virus\/hepatitis C virus-coinfected patient with hemophilia in Japan: a case report","volume":"52","author":"Eguchi","year":"2020","journal-title":"Transplant Proc"},{"key":"2025052712074654400_ofaf119-B21","doi-asserted-by":"crossref","first-page":"2054358117695792","DOI":"10.1177\/2054358117695792","article-title":"First Canadian case report of kidney transplantation from an HIV-positive donor to an HIV-positive recipient","volume":"4","author":"Ambaraghassi","year":"2017","journal-title":"Can J Kidney Health Dis"},{"key":"2025052712074654400_ofaf119-B22","doi-asserted-by":"crossref","first-page":"e003028","DOI":"10.1136\/bmjopen-2013-003028","article-title":"Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV","volume":"3","author":"Cohen","year":"2013","journal-title":"BMJ Open"},{"key":"2025052712074654400_ofaf119-B23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/1120009X.2021.1940436","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide combination in the management of kidney transplant patients with HIV receiving immunosuppressants","volume":"34","author":"Lagoutte-Renosi","year":"2022","journal-title":"J Chemother"},{"key":"2025052712074654400_ofaf119-B24","article-title":"Bictegravir or dolutegravir-containing antiretroviral regimens in solid organ transplantation: single-center experience","author":"Sherman","year":"2022"},{"key":"2025052712074654400_ofaf119-B25","first-page":"286","article-title":"Use of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in kidney transplant recipients living with HIV-1 receiving calcineurin and mTOR inhibitors: a pilot switch study","author":"Gallien","year":"2024"},{"key":"2025052712074654400_ofaf119-B26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40262-016-0424-1","article-title":"Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors","volume":"56","author":"Podany","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2025052712074654400_ofaf119-B27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1128\/AAC.00842-09","article-title":"Pharmacokinetics and safety of S\/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers","volume":"54","author":"Min","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025052712074654400_ofaf119-B28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"2025052712074654400_ofaf119-B29","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2025052712074654400_ofaf119-B30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/tid.12545","article-title":"Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient","volume":"18","author":"Lee","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"2025052712074654400_ofaf119-B31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"2025052712074654400_ofaf119-B32","doi-asserted-by":"crossref","first-page":"1295217","DOI":"10.3389\/fmed.2024.1295217","article-title":"A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy","volume":"11","author":"Hanser","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2025052712074654400_ofaf119-B33","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jac\/dkx365","article-title":"Dolutegravir-induced hyperglycaemia in a patient living with HIV","volume":"73","author":"McLaughlin","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025052712074654400_ofaf119-B34","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","article-title":"Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial","volume":"4","author":"Sax","year":"2017","journal-title":"Lancet HIV"},{"key":"2025052712074654400_ofaf119-B35","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1358\/dot.2019.55.11.3068796","article-title":"Bictegravir, a novel integrase inhibitor for the treatment of HIV infection","volume":"55","author":"Zeuli","year":"2019","journal-title":"Drugs Today (Barc)"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf119\/62278799\/ofaf119.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf119\/62278799\/ofaf119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/4\/ofaf119\/62278799\/ofaf119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:08:08Z","timestamp":1748362088000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf119\/8052775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf119","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,12]]},"article-number":"ofaf119"}}